The data are incrementally positive but do not change the binary nature of the Q4 2026 PDUFA decision. Monitor FDA advisory committee meeting (if any) and the final label for post-injection delirium/sedation syndrome (PDSS) risk, which has historically limited olanzapine LAI uptake.
Price Chart
Executive Summary
Teva presented new post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting injectable olanzapine for schizophrenia, at Psych Congress 2026. The data showed that over half of participants achieved stabilization, few relapsed, and over one-fifth of those treated for ≥6 months met remission criteria. A PDUFA decision from the FDA is expected in Q4 2026, making this a pre-catalyst update with no change in approval probability.
Key Facts
- TEV-'749 is an investigational once-monthly subcutaneous LAI of olanzapine for schizophrenia, not yet approved by any regulatory authority.
- Post hoc analysis of SOLARIS open-label period: 56% of 411 participants achieved stabilization; only 4% of stabilized participants relapsed.
- Among 183 participants treated ≥6 months, 21% met remission criteria (PANSS score ≤3 for ≥6 consecutive months).
- Switching simulations showed predictable olanzapine exposures within therapeutic ranges when switching from oral or short-acting IM olanzapine.
- Metabolic profile of TEV-'749 was consistent with daily oral olanzapine, with no clear dose-dependent pattern.
- PDUFA decision from FDA expected in Q4 2026; EU MAA accepted in May 2026.
- TEV-'749 uses SteadyTeq™ copolymer technology licensed from Medincell.
Financial Impact
No financial figures disclosed. TEV-'749 is pre-commercial; revenue potential depends on FDA approval and market adoption in the schizophrenia LAI market.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, delaying or blocking approval.
- Post-injection delirium/sedation syndrome (PDSS) risk associated with olanzapine LAIs may limit commercial adoption even if approved.
- Competition from existing LAIs (e.g., Invega Sustenna, Aristada, Abilify Maintena) and UZEDY (Teva's own risperidone LAI) could limit market share.
- Refinancing of ~$4.5B in higher-coupon debt (per cross-filing 424B5) is credit-positive but does not change TEV-'749's standalone approval risk.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364951 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $39.22 | awaiting T+60 | — | $40.39 (+2.98%) |
Oct 15, 2026 12d ago | Institutional Cluster | $41.11 | awaiting T+60 | — | $40.39 (+1.75%) |
Oct 8, 2026 19d ago | 3 | $41.10 | awaiting T+60 | — | $40.39 (−1.73%) |
Oct 2, 2026 25d ago | Press Release | $39.53 | awaiting T+60 | — | $40.39 (+2.18%) |
Oct 2, 2026 25d ago | Press Release | $39.53 | awaiting T+60 | — | $40.39 (+2.18%) |
Sep 30, 2026 27d ago | Press Release | $39.31 | awaiting T+60 | — | $40.39 (+2.75%) |
Sep 28, 2026 29d ago | Press Release | $39.81 | awaiting T+60 | — | $40.39 (+1.46%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $40.39 (+0.42%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $40.39 (+0.42%) |
Sep 22, 2026 5w ago | Insider Cluster | $39.01 | awaiting T+60 | — | $40.39 (−3.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers